Researcher Profile Statistics: Clara Angelina
Geo Map
Region
#
NA - North America
5
AS - Asia, other
4
EU - Europe
4
Unknown
1
Total
14
Country
#
US - United States of America
4
SG - Singapore
2
CA - Canada
1
FR - France
1
HK - Hong Kong
1
IE - Ireland
1
IN - India
1
IT - Italy
1
NO - Norway
1
Unknown
1
Total
14
City
#
Boardman
3
Singapore
2
Dublin
1
Hong Kong
1
Kolkata
1
Oslo
1
Padova
1
Paris
1
St Louis
1
Vaughan
1
other
1
Total
14
Bitstream
Downloads
ID: 1482743 - Pro-metastatic and mesenchymal gene expression signatures characterize circulating tumor cells of neuroblastoma patients wit.pdf - ITEM:( 10635/239175)
12
Total: {0}
12
Most bitstream per type viewed
#
ID: other -
0
ID: journal -
14
ID: conference -
0
ID: patent -
0
ID: allItems -
0
ID: book -
0
ID: dataset -
0
ID: selected -
0
Total
14
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Tot
2023
0 0
0 0 1 0
0 0 2 4
3 0
10
2024
0 1
2 0 1 0
0 0 0 0
0 0
4
Ever
14
Geo Map
Region | # |
---|---|
NA - North America | 5 |
AS - Asia, other | 4 |
EU - Europe | 4 |
Unknown | 1 |
Total | 14 |
Country | # |
---|---|
US - United States of America | 4 |
SG - Singapore | 2 |
CA - Canada | 1 |
FR - France | 1 |
HK - Hong Kong | 1 |
IE - Ireland | 1 |
IN - India | 1 |
IT - Italy | 1 |
NO - Norway | 1 |
Unknown | 1 |
Total | 14 |
City | # |
---|---|
Boardman | 3 |
Singapore | 2 |
Dublin | 1 |
Hong Kong | 1 |
Kolkata | 1 |
Oslo | 1 |
Padova | 1 |
Paris | 1 |
St Louis | 1 |
Vaughan | 1 |
other | 1 |
Total | 14 |
Bitstream | Downloads |
---|---|
ID: 1482743 - Pro-metastatic and mesenchymal gene expression signatures characterize circulating tumor cells of neuroblastoma patients wit.pdf - ITEM:( 10635/239175) | 12 |
Total: {0} | 12 |
Most bitstream per type viewed | # |
---|---|
ID: other - | 0 |
ID: journal - | 14 |
ID: conference - | 0 |
ID: patent - | 0 |
ID: allItems - | 0 |
ID: book - | 0 |
ID: dataset - | 0 |
ID: selected - | 0 |
Total | 14 |
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Tot | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 4 | 3 | 0 | 10 |
2024 | 0 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
Ever | 14 |